News – Page 2 – Alligator Bioscience

2024-11-06

Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024

The data contain efficacy results and correlative outcomes with biomarkers based on a median follow-up of 18 months in OPTIMIZE-1 trial Conf ...

2024-10-31

Regulatory

Lund, Sweden, October 31, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in prepa ...

2024-10-30

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces participation in the following conferences during Q4 202 ...

2024-10-29

LUND, SWEDEN and SEATTLE WA / October 29, 2024 / Alligator Bioscience AB (“Alligator”) (ATORX) and Aptevo Therapeutics (“A ...

2024-10-24

Regulatory

Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancer Positive interim Phase 1 ...

2024-09-16

Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types Prolonged stable disease lasting >11 months demonstrate ...

2024-09-13

Lund, Sweden and Seattle, Washington, September 13, 2024 – Alligator Bioscience AB (“Alligator”) (Nasdaq Stockholm: ATORX) ...

2024-07-112024-07-11

Regulatory

Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase ...

2024-07-10

Recruitment completed for the additional cohort with 450 µg/kg of mitazalimab in combination with mFOLFIRINOX as requested by FDA ahea ...